

NIH funding opportunities

22 Jan 2024 (#02)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-OD-24-048](#) The purpose of this notice is to extend the expiration date for the Notice of Funding Opportunity (NOFO) [PA-20-272](#) “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).” The purpose of this notice is to extend the expiration date for the Notice of Funding Opportunity (NOFO) [PA-20-272](#) “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).” Expiration Date: January 24, 2025.

[NOT-AI-24-014](#) **2024 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2024-1.** The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH. **Research Areas 001, 002, and 003:** For FY 25, the NIAID estimates up to \$16 million for the award of 5 cost reimbursement type base contracts across all three Research Areas (001, 002 & 003).

Research Area 001: Vaccine Candidates; Research Area 002: Therapeutic Candidates; Research Area 003: In Vitro Diagnostics. Proposals submitted in response to the BAA Solicitation must be received by **3:00 p.m. Eastern Standard Time on March 12, 2024**.

Parent Announcements

[NOT-OD-23-105](#) **Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates
Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

1. [NOT-CA-24-016](#) **Exploratory Cancer Immunology Projects and Technologies (ExCITE)**. Through this NOSI on Exploratory Cancer Immunology Projects and Technologies (ExCITE), the National Cancer Institute intends to encourage R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. Research projects should focus on fundamental areas of cancer immunology, including innate and adaptive immune responses, tumor-immune ecosystems and their dynamic interactions, the immune response to metastases, systemic immune networks, immunosurveillance, tumor immune evasion, or immunomodulation. Projects should be distinct in scope and focus from those supported through the traditional R01 mechanism. ExCITE studies may involve considerable risk but have the potential to lead to research breakthroughs or the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in cancer immunology and cancer immunotherapy research. This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026.
2. [NOT-OD-24-038](#) **Health Influences of Gender as a Social and Structural Variable**. The National Institutes of Health (NIH) vision for women's health is a world in which the influences of sex and gender are rigorously integrated into the health research enterprise. For the purposes of this Notice, [sex](#) refers to a set of biological variables, including anatomy, physiology, genetics, and hormones. For the purposes of this Notice, [gender](#) refers to a set of social and structural variables that encompass gender identity and expression, gender roles and norms, gender relations, and gender power systems (e.g., structural sexism). Sex-linked biology and gender-related factors can act independently or interactively to influence health. As a social, cultural, and structural construct, gender encompasses multiple domains. Many other social variables including race, ethnicity, disability, sexual orientation, socioeconomic status, and education intersect with gender to impact health and disease in unique ways. Intersectional frameworks enable consideration of how these socially determined categories overlap and interact to create disparate and inequitable outcomes for individuals and communities. This NOSI applies to due dates on or after January 25, 2024, and subsequent receipt dates through September 30, 2025.
3. [NOT-MH-24-100](#) **Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors**. This NOSI solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. These studies are expected to utilize recent tools that enable precise assessment of spatiotemporal dynamics of extracellular release or receptor activation of neuromodulators with simultaneous causal interrogation of neural activity and behavioral responses. This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through May 10, 2027.
4. [NOT-MH-24-105](#) **Fundamental Mechanisms and Functions of Co-transmission in the Brain**. This NOSI encourages basic neuroscience research in animals to investigate the fundamental mechanisms and functions of co-transmission (i.e., release of multiple neurotransmitters by one neuron) that support brain activity and behavior. This Notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 4, 2027.
5. [NOT-OD-24-031](#) **Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)**. The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to

develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or biomedical and/or health-related behavioral research. The proposed bioethics question, issue, or topic must be clearly articulated. All applications must be within the scope of the parent award. The proposed studies cannot expand the scope of the parent award. Application Due Date April 1, 2024, by 5:00 PM local time of applicant organization.

Notice of Funding Opportunity (NOFO)

1. **[PAR-24-060](#) Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional).** The purpose of this notice of funding opportunity (NOFO) is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this NOFO include a reduction in negative sequelae of use, such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.

Due dates: February 16, 2024 through to January 07, 2027. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date. **Budget:** Applicants may request direct costs of up to \$450,000 for three years. Although variations from year to year are permissible, in no case may any year be more than \$225,000 in direct costs, and total direct costs for the entire project period may not exceed \$450,000. The maximum project period is three years.

2. **[RFA-DA-25-007](#). Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed).** The purpose of this notice of funding opportunity (NOFO) is to support research on (1) the development of novel tools, methods, and molecular probes to identify mechanisms and signaling pathways by which addictive substances influence HIV latency and transcriptional reactivation in the central nervous system (CNS), and (2) identification and functional validation of novel lead compounds that suppress HIV transcription in the context of addictive substances. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Due dates: August 13, 2024 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are limited to \$400,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. **[RFA-DA-25-028](#) Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional).**

Due dates: July 09, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are expected not to exceed \$500,000 per year in direct costs. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

4. **[RFA-FD-24-015](#) Public Health Regulatory Systems Strengthening - U01 Clinical Trials Not Allowed.** The purpose of the Public Health Regulatory Systems Strengthening NOFO is to partner with the Organization for Economic Co-Operation and Development (OECD), primarily to address the growing threat of illicit trade in health products (drugs, vaccines, medical devices, food) through the development of a whole-of-governments approach that relies on targeted, risk based, and efficient data driven models. The data will be used to develop mitigation strategies and potential regulatory and enforcement solutions that address substandard, misleading, and falsified food and medical

products sold both in informal markets and through legitimate channels and raise the profile and awareness of this issue within the global community. The proposed cooperative agreement will also include work on other FDA public health topics of interest, including, but not limited to, addressing mis- and dis-information; strengthening regulatory frameworks by advancing health equity; promoting the use of good regulatory practices to develop regulations that are efficient, transparent, modern, and based on science and risk principles; and enhancing patient engagements in product development and quality of care.

Due dates: February 29, 2024 or [Standard dates](#) apply. All applications are due by 11:59 PM Eastern Time on the application due date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for FOUR (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. Application budgets are not limited but need to reflect the actual needs of the proposed project. \$150 000 per year. The scope of the proposed project should determine the project period. The maximum project period is five (5) years.

5. [RFA-FD-24-026](#) Strengthening Global Competency and Capacity in Inspectional Approaches for the Oversight of Human and Animal Pharmaceutical Products (U01) Clinical Trials Not Allowed. The Cooperative Agreement will build upon the extensive experience of an institution with well-established and globally recognized expertise and quality standards for drug inspectorates of National Regulatory Authorities (NRAs) around the globe in support of data-driven and science-based regulatory public health strategies and approaches. The organization's best practices should align with the FDA domestic and global priority of assuring of the integration of pharmaceutical good manufacturing practice (GMP) inspections and risk assessment activities including data modeling for a risk-based inspection prioritization and workplan. The funding will catalyze and support the institution's activities that are focused on building a global consensus on criteria for an optimal good manufacturing practice inspection, the core competencies for Inspectors or investigators, and planning, prioritizing and conducting inspections based on well informed risk assessments within the context of the increasingly complex and evolving science and innovation in the manufacturing of pharmaceutical products. Based on such consensus, the institution and its network of NRA Inspectorates will work toward a systems-approach and sustainable alignment across NRA Inspectorates in training inspectors and regulatory experts in best practices for maintaining oversight of pharmaceutical supply chains.

Due dates: February 27, 2024 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for FOUR (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/OC/OPLIA/OGPS intends to fund up to \$150,000, for fiscal year 2024 in support of this grant program. It is anticipated that up to 1 (one) award will be made, not to exceed \$150,000 in total costs (direct plus indirect), per award.

6. [PAR-23-319](#) Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional). The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the [Global Alliance for Chronic Diseases](#) (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in [World Bank-defined low- and middle-income countries](#) (LMICs) and American Indian/Alaska Native (AI/AN) populations in the United States (US). Air, water, and soil pollution; lack of greenspace; urban heat islands; lack of safe infrastructure for walking, cycling, and active living; lack of access to healthcare facilities, lack of health insurance, and cost of medications; housing condition; and wide availability of tobacco, alcohol, and unhealthy foods and beverages contribute to the NCD epidemic in city environments. In the context of this Notice of Funding Opportunity (NOFO), "cities" include urban centers, informal settlements, slums, and periurban areas. This NOFO supports applications that propose implementation research to reduce the risks of NCDs in the context of cities in LMICs and/or among AI/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. NIH defines implementation research as the scientific study of the use of strategies to adopt and integrate evidence-based health interventions into clinical and community settings to improve individual outcomes and benefit population health.

Due dates: March 11, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. [PAR-24-072](#) Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required).

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

Due dates: February 05, 2024 through to January 07, 2027. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

8. [PAR-24-085](#) National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required).

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.

Due dates: February 05, 2024 through to January 07, 2027. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are limited to no more than \$499,999 in direct costs per year. The maximum project period is 5 years.

9. [PAR-24-088](#) Discovery of *in vivo* Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed).

The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of *in vivo* chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Due dates: February 05, 2024 through to October 05, 2026. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. maximum project period is 5 years.

10. [PAR-24-091](#) Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional).

This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives:

1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and

2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches.

Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH's Office of AIDS Research (OAR), as described in [NOT-OD-20-018](#).

Due dates: June 05, 2024 through to May 07, 2027. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. maximum project period is 5 years.

11. [RFA-AI-23-068](#) Bat Immunology Network Research Projects (R01 Clinical Trial Not Allowed) The purpose of this Notice of Funding Opportunity (NOFO) is to support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats. Research projects supported by this NOFO will form a collaborative research network to advance understanding of the bat immune response.

Due dates: May 24, 2024. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIAID intends to commit an estimated total of \$2 million in FY 2025 to fund 4-5 awards. Awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not expected to exceed \$300,000 in Direct Costs per year and must reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

12. [RFA-CA-24-016](#) Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's [Informatics Technology for Cancer Research](#) (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity.

Due dates: June 11, 2024; November 15, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NCI intends to fund an estimate of 5 awards, corresponding to a total of \$1,020,000, for fiscal year 2025. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

13. [RFA-CA-24-017](#) Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Due dates: June 11, 2024; November 15, 2024. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date. **Budget:** NCI intends to commit \$2,250,000 in FY 2025 to fund 5-6 awards. Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is three years.

Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 K th Floor, Teaching Block, Tygerberg Campus.	Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street
Enquiries: cdevries@sun.ac.za / fmhsgmo@sun.ac.za	Enquiries: research@sun.ac.za
Add “Interest in NIH opportunity” in the subject line. Add the notice number in the text of the email.	